Viibryd (vilazodone) carried a high price tag for over a decade because it was a brand-name antidepressant with no generic competition. The good news: its patent expired in June 2022, and generic versions are now available for around $40 a month, a fraction of what the brand once cost. But depending on your pharmacy, your insurance, and whether you’re still being dispensed the brand name, you may still be paying far more than you need to.
What Kept the Price High for So Long
Viibryd launched in 2011 as the only antidepressant in its class. It combines two mechanisms into one pill: it blocks the reabsorption of serotonin (like a standard SSRI) and simultaneously stimulates a specific serotonin receptor, similar to the anti-anxiety drug buspirone. This combination earned it its own pharmacological category. That novelty gave the manufacturer strong patent protection and no direct competitors to drive prices down.
The key patent didn’t expire until June 5, 2022, giving the manufacturer roughly 11 years of market exclusivity. During that window, a month’s supply of brand-name Viibryd commonly ran several hundred dollars at retail. Without a generic alternative, patients and insurers had limited leverage on price. Insurance plans that did cover it often placed it on a higher formulary tier with steep copays, and some plans required prior authorization or step therapy, meaning you had to try cheaper antidepressants first.
Generic Vilazodone Is Now Available
The FDA actually began approving generic versions of vilazodone before the patent expired. Teva Pharmaceuticals received approval in September 2019, followed by Alembic in January 2020 and InvaGen in April 2021. Since the patent lapsed in mid-2022, multiple additional companies have entered the market, including Cipla, Apotex, Accord Healthcare, and several others. That growing competition has pushed the generic price down significantly.
As of the most recent pricing data, generic vilazodone costs roughly $40 per month, and the price may continue to drop as more manufacturers compete. That’s a dramatic reduction from the brand-name cost, which could exceed $400 for a 30-day supply without insurance.
Why You Might Still Be Paying Too Much
Even with generics on the market, some patients report high out-of-pocket costs. A few common reasons explain the gap.
- Your pharmacy is dispensing the brand. If your prescription is written for “Viibryd” and your state or pharmacy doesn’t automatically substitute the generic, you could be paying brand prices unnecessarily. Ask your pharmacist or prescriber to switch to generic vilazodone.
- Your insurance formulary is restrictive. Some plans place vilazodone on a higher cost tier. For example, UnitedHealthcare’s 2025 Medicare Part D formulary lists generic vilazodone on Tier 4 with quantity limits, and doesn’t cover brand-name Viibryd at all. A Tier 4 placement typically means higher copays than you’d pay for a standard generic antidepressant like sertraline or escitalopram.
- You don’t have prescription coverage. Without insurance, even the generic can cost more than $40 depending on the pharmacy. Prices vary widely between retailers, and discount programs like GoodRx or RxSaver can sometimes bring the cost below what you’d pay through insurance.
Why It Costs More Than Other Antidepressants
Generic vilazodone at $40 a month is affordable compared to where it was, but it’s still pricier than many first-line antidepressants. Generic sertraline (Zoloft), fluoxetine (Prozac), and escitalopram (Lexapro) often cost under $10 a month. The price difference comes down to market maturity. Those SSRIs have been generic for 10 to 20 years, with dozens of manufacturers competing. Vilazodone’s generic market is younger and smaller, so prices haven’t bottomed out yet.
There’s also a question of demand. Vilazodone occupies a niche. While its dual mechanism was marketed as an advantage, clinical evidence hasn’t clearly shown it outperforms standard SSRIs for most patients with depression. The Carlat Psychiatry Report noted that even with the generic now available, the drug’s clinical profile raises questions about whether it offers enough benefit over cheaper alternatives to justify routine prescribing. For patients who respond well to vilazodone specifically, it remains a valid option. But the smaller patient base means fewer manufacturers have incentive to aggressively compete on price.
How to Lower Your Cost
If you’re currently taking Viibryd and paying more than you’d like, the most immediate step is confirming you’re getting the generic. Check your prescription label for “vilazodone” rather than “Viibryd.” If it still says the brand name, call your prescriber’s office and ask them to update the prescription to allow generic substitution.
Compare prices across pharmacies before filling. Costco, Walmart, and independent pharmacies sometimes offer significantly lower cash prices than chain drugstores. Online pharmacy discount tools can show you real-time pricing at nearby locations. If you’re on Medicare or commercial insurance and the copay is still high because of formulary placement, your prescriber can sometimes submit a prior authorization or formulary exception request to get it covered at a lower tier.
For patients without insurance, AbbVie (which markets brand-name Viibryd) has historically offered patient assistance programs, though eligibility requirements and availability change over time. The generic manufacturers don’t typically offer their own savings programs, making pharmacy shopping and discount cards the most reliable routes to a lower price.